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Background: NKX2-1 related disorders (also known as brain-lung-thyroid syndrome
or benign hereditary chorea 1) are associated with a wide spectrum of symptoms.
The core features are various movement disorders, characteristically chorea, less
frequently myoclonus, dystonia, ataxia; thyroid disease; and lung involvement. The full
triad is present in 50% of affected individuals. Numerous additional symptoms may
be associated, although many of these were reported only in single cases. Pituitary
dysfunction was ambiguously linked to NKX2-1 haploinsufficiency previously.
Case Presentation: We examined two members of a family with motor
developmental delay, mixed movement disorder (myoclonus, dystonia and chorea)
and endocrinological abnormalities (peripheric thyroid disease, and pituitary hormone
deficiencies). Dystonia predominated at the father, and myoclonus at the daughter.
The father had hypogonadotropic hypogonadism, while the daughter was treated
with growth hormone deficiency. Both patients had empty sella on MRI. Candidate
gene analyses were negative. Exome sequencing detected a pathogenic stop variation
(NM_003317:c.338G>A, p.Trp113∗) in the NKX2-1 gene.
Conclusions: This case study has two highlights. (1) It draws attention to possible
pituitary dysfunction in brain-lung-thyroid syndrome, and provide further evidences that
this might be linked to loss of function of the NKX2-1 gene. (2) It underscores the
importance of considering NKX2-1 related disorders in the differential diagnosis of
myoclonus dystonia.
Keywords: NKX2-1 gene, NKX2-1 related disorders, benign hereditary chorea, brain-lung-thyroid syndrome,
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INTRODUCTION
NKX2-1 (TTF1) related disorders are associated with a wide spectrum of symptoms, which
may be present in various combinations. The most frequently reported symptoms are related to
alterations in the central nervous system, thyroid or lung tissues, hence the name brain-lung-
thyroid disorder (Peall and Kurian, 2015). Brain involvement may manifest among other things
as motor developmental delay, hypotonia, chorea, myoclonus, ataxia, drop attacks, and psychiatric
disorders. The neurologic syndrome is also known as benign hereditary chorea (OMIM 118700)
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because the disease is typically non-progressive. Thyroid
involvement manifests as congenital hypothyroidism, or thyroid
agenesis, while lung involvement may be present as infant
respiratory distress syndrome, recurrent pulmonary infections,
and interstitial lung disease. Besides the core features, many other
associated features were described such as malignancies, short
stature, skeletal abnormalities, hypoparathyroidism (Peall and
Kurian, 2015). One case was reported in the literature, where
growth hormone (GH) deficiency was documented in association
with a whole gene deletion (Peall et al., 2014b). However, whether
this was incidental or could be linked to the NKX2-1 mutation
was equivocal.
PATIENTS AND METHODS
Here we present the case of two affected members of a family
(Patient II/2 and III/1 on Figure 1), who—besides the motor
phenotype- show evidence for the involvement of the pituitary,
associated with an NKX2-1 point mutation. This article is a
retrospective case study; it has an institutional ethical committee
approval. Informed consent for diagnostic genetic testing was
obtained from each individual. The patients gave informed,
written consent for publication of the history, examinations, and
videos.
For exome sequencing genomic DNA library preparation
was performed by using Agilent SureSelectQXT Human
All Exon v5 reagents (Agilent Technologies, Santa Clara,
CA, USA) according to the manufacturer’s protocol. Library
preparation was followed by next-generation sequencing using
Illumina HiSeq PE Cluster Kit v4 for cluster generation on
cBot and HiSeq SBS Kit v4 for sequencing on HiSeq2500
system (Illumina, San Diego, CA, USA). Filtering of variants
was based on the inheritance pattern, allele frequency,
FIGURE 1 | Family tree of the affected family. We have examined patient II/2
and III/1. Family history suggested autosomal dominant inheritance.
and consequence of the mutation. Pathogenicity of the
variants was assessed as recommended by the American
College of Medical Genetics guideline 2015 (Richards et al.,
2015).
CASE PRESENTATION
Figure 1: Family Tree
Patient II/2 (46 years old at the time of exome sequencing)
presented with motor developmental delay. He started to
walk at age 2 years, but the gait was always unsteady. At the
age of 6 years, child neurologist described ataxic gait, with
appendicular dyskinesias, which were mainly noticeable during
the walk. During elementary school, hyperkinetic movements
were increasing, but not disabling for the patient. During high
school years, perioral hyperkinesis also developed. Later the
coordination problems and hyperkinetic symptoms slowly
progressed, and after the age of 35 years, he was not able to
work anymore as a tailor. Besides hyperkinetic movements,
cervical dystonia also developed, later bothersome myocloni
appeared in the diaphragm. At the age of 45 years a low
testosterone and low luteinizing hormone (LH) level was
detected in the background of erectile dysfunction. He received
subcutaneous human chorionic gonadotropin (hCG), and later
intramuscular testosterone-undecanoate treatment. Elevated
thyroid-stimulating hormone (TSH) level was also detected
at the patient, he underwent levothyroxine supplementation.
Because of asthma the patient was treated by a pulmonologist as
well. Repeated brain MRIs showed cave of septum pellucidum
and empty sella (Figure 2). Abdominal ultrasound showed
diffuse increased echogenicity of the liver, corresponding
to hepatic steatosis. Earlier candidate gene examinations
(SCA1,2,3,6,7,17 repeat expansion analysis, IT15 repeat
analysis, POLG, DYT1 gene sequencing) were negative. At
the time of the exome sequencing, hyperkinetic movements
were already treated with tetrabenazine, and the patient
regularly received botulinum toxin for his cervical dystonia.
Supplementary Video S1 shows elements of the neurological
examination. We detected mild perioral hyperkinesis, dysarthria,
mild (treated) cervical dystonia. Myocloni were present in
the abdominal musculature, and mild choreiform movements
in the extremities, fingers, and trunk, which were increasing
during walk. Mild spasticity and dystonia was noticed in the
lower extremities, but pyramidal signs were not present. In
Romberg position, mild unsteadiness was present, but nor gait
neither appendicular ataxia was detected. His mother (I/1) had
similar movement difficulties as described by the patient, but
we could not examine her, because she died earlier due to colon
cancer.
His daughter (Patient III/1, 20 years old at the time of the
exome sequencing) also experienced motor developmental delay.
She started to walk around age of 1.5 year, but she was unsteady.
Gait ataxia, muscle hypotony, and myoclonic hyperkineses were
described at that time by a pediatric neurologist. Hyperkineses
were noticed at age 4 years, falls occurred at age 5 years.
Later, the intensity of hyperkineses increased. Because of low
stature, insulin tolerance test with measurement of growth
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FIGURE 2 | Brain MR images of the examined patients. T1 weighted images of Patient II/2 (A,B), and of Patient III/1 (C). Image (A) and (C) demonstrate empty sella
on sagittal images. Infundibulum sign is identifiable (arrows), thus proving empty sella vs. cystic mass of pituitary.
hormone (GH) level was performed at age of 13 years. No
GH elevation was detected (GH remained under 10 ng/mL).
Brain MRI showed an empty sella (Figure 2). She received
subcutaneous GH between the age of 13–17 years, and she
reached a normal height. TSH level was normal. During
elementary school, the performance was always somewhat below
the average. An educational psychologist diagnosed dyslexia,
with normal IQ. Later at age of 18 years, marginal IQ was
measured (83 points in the Wechsler test 83). She started high-
school education, but was unable to keep up with lectures.
Around the age of 18 years, psychiatric symptoms emerged with
exaggerated anxiety, depression and suicidal temptation. She
was treated with a transient psychotic episode after an induced
abortion, because of unwanted pregnancy. Former candidate
genetic studies were negative (SCA1,2,3 repeat expansion, GNAL,
RELN, DYT11, DYT5, DYT14 sequencing). Elements of the
neurologic examination at age of 20 years are shown on the
Supplementary Video S2. Mild microcephaly, underdeveloped
secondary sex characteristics, and joint hypermobility were
noticed. Continuous choreiform movements were detected in
the head, trunk and extremities, with superimposed myocloni.
Dysarthria was noticeable as well. Mild spasticity and Babinski
sign was detected in the right lower limb. Ataxia was not
present.
Figure 2: Brain MRIs of the Patients
Myoclonus dystonia was suspected first at the family, given
the pronounced myoclonus at the daughter and predominant
dystonic features at the father, but targeted SGCE sequencing
was negative. Exome sequencing was then performed at the two
patients. A pathogenic heterozygous stop variant was detected
in both patients in the NKX2-1 gene: NM_003317:c.338G>A,
p.Trp113∗. This variant was not present in the ExAc, 1000G,
ClinVar, dbSNP databases, nor in our exome cohort of 200
individuals. Pathogenic variants of the NKX2-1 gene are
associated with the brain-lung-thyroid syndrome, which is
compatible with the phenotype of the patients. After the
diagnosis, TSH screening was performed at the daughter, with
normal results. Chest X-ray was normal in both patients.
DISCUSSION AND CONCLUSIONS
While retrospectively most of the symptoms are consistent with
the literature, this case study has two highlights. Firstly, it
draws attention to possible pituitary dysfunction in brain-lung-
thyroid syndrome, and provide further evidences that this might
be linked to loss of function of the NKX2-1 gene. Secondly,
it underscores the importance of considering NKX2-1 related
disorders in the differential diagnosis of myoclonus dystonia.
Both of our patients showed evidence of pituitary dysfunction.
The father had low LH levels, leading to hypogonadism, while
the daughter had low GH levels, causing her low stature. Besides,
the pituitary of both patients was structurally also affected, as
they had empty sella. Only scarce information is available in
the literature about pituitary dysfunction in humans in brain
lung thyroid syndrome. Current evidences suggest that probably
loss of function of NKX2-1 gene associates with the pituitary
abnormalities, however this must be further investigated by
functional studies. In the cohort of Peall et al. (Peall et al.,
2014b), one patient with a whole NKX2-1 gene deletion had
growth hormone deficiency. Salvatore et al. reported a family
with congenital hypothyroidism, where two patients had empty
sella on brain MRI associating with a stop mutation of NKX2-1
gene (Salvatore et al., 2010). However no information is available
about the pituitary hormones in this family. Accornero et al.
reported a patient with duplication of the pituitary stalk and
subclinical hypothyroidism, who had a heterozygous 1.2Mb
deletion containing the NKX2-1, MBIP, NKX2-8, PAX-9, and
SLC25A1 gene (Accornero et al., 2010). This patient showed
an exaggerated response of prolactine to TRH, but otherwise
the hypothalamus-pituitary-gonadal, -somatotropic and -adrenal
axis function was normal. One family, with a nonsense variant,
reported by Veneziano et al., showed evidence of cystic pituitary
masses (Veneziano et al., 2014). This patient had primary
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hypothyroidism, but the remainder of the pituitary hormonal
profile was normal.
From the study of NKX2-1 (TTF-1) in the mouse, it is known,
that it has important roles in the developing brain. Indeed,
it is responsible for the interneuron specification of medial
ganglionic eminence cells (Butt et al., 2008), and the regulation
of the direction of the migrating interneurons (Nóbrega-Pereira
et al., 2008). TTF1 knockout mice lack the pituitary gland
(Takuma et al., 1998). Postnatally it regulates GH and prolactin
transcription in the rat pituitary (Lee et al., 2007) and has
also been shown to play a role in the regulation of circadian
changes in gonadotropin-releasing hormone (GnRH) expression
(Matagne et al., 2012). Therefore, NKX2-1 haploinsufficiency is
a plausible explanation for the symptoms of our patients. Our
case report serves as further evidence for the involvement of both
pituitary development, and function inNKX2-1 related disorders
in humans. However, this aspect of the syndrome is needed to be
further studied in a cohort of patients.
Another important note to this case is the necessity of
remembering NKX2-1 gene in the differential diagnosis of
myoclonus dystonia. In our case, the predominant dystonia in
the father and frequent myocloni in the daughter led probably
to the targeted testing of other movement disorder associated
genes. Our first hypothesis focused on myoclonus dystonia, but
SGCE testing was negative. It is known from the literature that
NKX2-1 related disorders may resemble myoclonus-dystonia.
However certain features may help the clinical diagnosis, such
as aggravation of myoclonic jerks with movements in SGCE
positive patients, and continuous chorea in NKX2-1 positive
patients (Asmus et al., 2007). In contrast with this observation,
at the studied family the father’s hyperkinesis worsened with
movements, especially during gait. On the other hand, the
predominant motor phenotype was dystonia at him. The
daughter showed myoclonic jerks, superimposed on continuous
chorea. In the study of Peall et al. (2014a), from 70 suspected
myoclonus-dystonia patients, negative for SGCE mutations, two
cases were found to have putative NKX2-1 mutations, and no
mutations were detected in the DYT1, GCH1, THAP1 genes.
In addition to these genes, ADCY5 need also be considered in
SGCE negative myoclonus dystonia (Chang et al., 2016).We have
non-systemically checked commercially available dystonia panels
(Supplementary Table 1) whether NKX2-1 was represented on
them. We also checked NCBI Genetic Testing Registry (https://
www.ncbi.nlm.nih.gov/gtr/) and looked specifically for NKX2-1
gene (geneid: 7080) whether the testing of this gene is present as a
member of a dystonia panel.We found only one from 11 dystonia
panels, on which this gene was present. Thus it is important to
bear in mind the NKX2-1 gene as a possibility in hyperkinetic
syndromes featuring any variety of dystonia, myoclonic jerks,
and chorea.
Both of our patients received tetrabenazine for the treatment
of chorea. The daughter hadmore severe phenotype, she received
12.5mg tetrabenazine three times a day. This reduced choreiform
movements, but significant chorea still remained. We could not
give larger doses because of sedation, and depression in the
history. As the patient had also pronounced gait impairment
we also tried levodopa, but she not tolerated even small doses
(levodopa/benserazide 50 mg/12.5mg three times a day). She
also received small dose of levetiracetam (2 × 12.5mg), which
had positive effect on myocloni. Depression and anxiety was
treated with escitalopram and alprazolam effectively. The fathers
choreiform movements were well controlled with 2 × 12.5mg
tetrabenazine, without side effects. Cervical dystonia was treated
effectively with botulinum toxin injections.
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